142 related articles for article (PubMed ID: 24856952)
1. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO; Reichart A; Bankstahl US; Pauligk C; Loose M; Kraus TW; Elshafei M; Bechstein WO; Trojan J; Behrend M; Homann N; Venerito M; Bohle W; Varvenne M; Bolling C; Behringer DM; Kratz-Albers K; Siegler GM; Hozaeel W; Al-Batran SE
Ann Surg Oncol; 2024 Jun; 31(6):4073-4083. PubMed ID: 38459418
[TBL] [Abstract][Full Text] [Related]
3. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.
Cloyd JM; Colby S; Guthrie KA; Lowy AM; Chiorean EG; Philip P; Sohal D; Ahmad S
J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38688309
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant strategies for pancreatic cancer.
Polistina F; Di Natale G; Bonciarelli G; Ambrosino G; Frego M
World J Gastroenterol; 2014 Jul; 20(28):9374-83. PubMed ID: 25071332
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.
Lim JE; Chien MW; Earle CC
Ann Surg; 2003 Jan; 237(1):74-85. PubMed ID: 12496533
[TBL] [Abstract][Full Text] [Related]
6. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
[TBL] [Abstract][Full Text] [Related]
7. Borderline Resectable and Locally Advanced Pancreatic Cancers: A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions.
Khachfe HH; Habib JR; Nassour I; Al Harthi S; Jamali FR
Pancreas; 2021 Oct; 50(9):1243-1249. PubMed ID: 34860806
[TBL] [Abstract][Full Text] [Related]
8. Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Frei L; Stieger R; Bayerl C; Breitenstein S; Staerkle RF
J Med Case Rep; 2017 Jul; 11(1):194. PubMed ID: 28716115
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Pardee T; Lima CMSR; Howerton R; Clark CJ; Shen P
J Surg Oncol; 2023 Oct; 128(5):844-850. PubMed ID: 37341164
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: advances in treatment.
Mohammed S; Van Buren G; Fisher WE
World J Gastroenterol; 2014 Jul; 20(28):9354-60. PubMed ID: 25071330
[TBL] [Abstract][Full Text] [Related]
11. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
[TBL] [Abstract][Full Text] [Related]
12. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study.
Han D; Gao F; Liu JL; Wang H; Fu Q; Yang GW
BMC Cancer; 2021 May; 21(1):560. PubMed ID: 34001035
[TBL] [Abstract][Full Text] [Related]
13. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy.
Irfan A; Rose JB; Wang TN; Vickers SM; Dudeja V; Gbolahan O; Reddy S
Pancreas; 2022 Jan; 51(1):100-105. PubMed ID: 35195602
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer.
Gleeson EM; Leigh N; Golas BJ; Magge D; Sarpel U; Hiotis SP; Labow DM; Pintova S; Cohen NA
Pancreas; 2021 Sep; 50(8):1163-1168. PubMed ID: 34714279
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
Dhir M; Malhotra GK; Sohal DPS; Hein NA; Smith LM; O'Reilly EM; Bahary N; Are C
World J Surg Oncol; 2017 Oct; 15(1):183. PubMed ID: 29017581
[TBL] [Abstract][Full Text] [Related]
16. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).
Farnes I; Kleive D; Verbeke CS; Aabakken L; Issa-Epe A; Småstuen MC; Fosby BV; Dueland S; Line PD; Labori KJ
BJS Open; 2023 Nov; 7(6):. PubMed ID: 38155512
[TBL] [Abstract][Full Text] [Related]
17. Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients.
Doyle J; Amundsen T; Hall JA; Raiyani C; Wong L
Pancreas; 2021 Aug; 50(7):1020-1023. PubMed ID: 34629453
[TBL] [Abstract][Full Text] [Related]
18. National failure to operate on early stage pancreatic cancer.
Bilimoria KY; Bentrem DJ; Ko CY; Stewart AK; Winchester DP; Talamonti MS
Ann Surg; 2007 Aug; 246(2):173-80. PubMed ID: 17667493
[TBL] [Abstract][Full Text] [Related]
19. Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer.
Liu M; Wei AC
Hematol Oncol Clin North Am; 2024 Jun; 38(3):629-642. PubMed ID: 38429197
[TBL] [Abstract][Full Text] [Related]
20. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis.
Xue K; Huang X; Zhao P; Zhang Y; Tian B
Int J Surg; 2023 Dec; 109(12):4309-4321. PubMed ID: 38259002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
